<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE nitf SYSTEM "http://www.nitf.org/IPTC/NITF/3.3/specification/dtd/nitf-3-3.dtd">
<nitf change.date="June 10, 2005" change.time="19:30" version="-//IPTC//DTD NITF 3.3//EN">
  <head>
    <title>ROCHE SALES INCREASE</title>
    <meta content="MB010525" name="slug"/>
    <meta content="18" name="publication_day_of_month"/>
    <meta content="10" name="publication_month"/>
    <meta content="2000" name="publication_year"/>
    <meta content="Wednesday" name="publication_day_of_week"/>
    <meta content="Business/Financial Desk" name="dsk"/>
    <meta content="1" name="print_page_number"/>
    <meta content="W" name="print_section"/>
    <meta content="5" name="print_column"/>
    <meta content="Health; Business" name="online_sections"/>
    <docdata>
      <doc-id id-string="1239829"/>
      <doc.copyright holder="The New York Times" year="2000"/>
      <series series.name="WORLD BUSINESS BRIEFING: EUROPE"/>
      <identified-content>
        <classifier class="indexing_service" type="descriptor">Drugs (Pharmaceuticals)</classifier>
        <classifier class="indexing_service" type="descriptor">Sales</classifier>
        <classifier class="indexing_service" type="descriptor">Skin</classifier>
        <classifier class="indexing_service" type="descriptor">Genetics and Heredity</classifier>
        <org class="indexing_service">Roche Holdings Ltd</org>
        <org class="indexing_service">Basilea Pharmaceutica</org>
        <person class="indexing_service">Olson, Elizabeth</person>
        <classifier class="online_producer" type="taxonomic_classifier">Top/News/Business</classifier>
        <classifier class="online_producer" type="taxonomic_classifier">Top/News/Business/World Business</classifier>
        <classifier class="online_producer" type="taxonomic_classifier">Top/Classifieds/Job Market/Job Categories/Pharmaceutical, Biotechnology and Science</classifier>
        <classifier class="online_producer" type="taxonomic_classifier">Top/News/Health</classifier>
        <classifier class="online_producer" type="taxonomic_classifier">Top/Classifieds/Job Market/Job Categories/Sales and Business Development</classifier>
        <classifier class="online_producer" type="general_descriptor">Sales</classifier>
        <classifier class="online_producer" type="general_descriptor">Drugs (Pharmaceuticals)</classifier>
        <classifier class="online_producer" type="general_descriptor">Genetics and Heredity</classifier>
        <classifier class="online_producer" type="general_descriptor">Skin</classifier>
        <classifier class="online_producer" type="general_descriptor">Medicine and Health</classifier>
      </identified-content>
    </docdata>
    <pubdata date.publication="20001018T000000" ex-ref="http://query.nytimes.com/gst/fullpage.html?res=9501E6DB143EF93BA25753C1A9669C8B63" item-length="84" name="The New York Times" unit-of-measure="word"/>
  </head>
  <body>
    <body.head>
      <hedline>
        <hl1>ROCHE SALES INCREASE</hl1>
      </hedline>
      <byline class="print_byline">By Elizabeth Olson</byline>
      <byline class="normalized_byline">Olson, Elizabeth</byline>
      <abstract>
        <p>Roche Holding says sales in first nine months of year rose 7.5 percent, to $11.4 billion; announces it will establish new biotechnology company called Basilea Pharmaceutica to focus on dermatology and anti-infection drugs; photo (S)</p>
      </abstract>
    </body.head>
    <body.content>
      <block class="lead_paragraph">
        <p>Roche Holding said sales in the first nine months of the year rose 7.5 percent, to $11.4 billion, helped by increased demand for diagnostic tests. Roche, based in Basel, Switzerland, also announced it would establish a new biotechnology company called Basilea Pharmaceutica to focus on dermatology and anti-infection drugs. Franz B. Humer, chief executive of Roche, said it was looking for investors for the new company and would keep a significant minority stake.</p>
        <p>Elizabeth Olson</p>
      </block>
      <block class="full_text">
        <p>Roche Holding said sales in the first nine months of the year rose 7.5 percent, to $11.4 billion, helped by increased demand for diagnostic tests. Roche, based in Basel, Switzerland, also announced it would establish a new biotechnology company called Basilea Pharmaceutica to focus on dermatology and anti-infection drugs. Franz B. Humer, chief executive of Roche, said it was looking for investors for the new company and would keep a significant minority stake.</p>
        <p>Elizabeth Olson</p>
        <p>WORLD BUSINESS BRIEFING: EUROPE</p>
      </block>
    </body.content>
  </body>
</nitf>
